v3.25.4
Other Income - Narrative (Details)
€ in Thousands
 1 Months Ended 12 Months Ended 13 Months Ended
Dec. 31, 2023
EUR (€)
Dec. 31, 2025
EUR (€)
Dec. 31, 2024
EUR (€)
Dec. 31, 2023
EUR (€)
Dec. 31, 2025
EUR (€)
Dec. 31, 2024
USD ($)
Jan. 31, 2024
EUR (€)
Feb. 09, 2018
USD ($)
Other Income [Line Items]                
Other income       € 5        
Grant income   € 441 € 640 75        
Net gain on divestment of intellectual property       2,931        
Proceeds from sales of intangible assets, classified as investing activities       7,940        
sepofarsen and ultevursen                
Other Income [Line Items]                
Gross proceeds from sale of intellectual property € 8,000              
Transaction costs on sale of intellectual property 5,069              
Net gain on divestment of intellectual property 2,931              
Transaction costs on sale of intellectual property, repayment of grants 1,117              
Transaction costs on sale of intellectual property, financial advisory fees 2,715              
Transaction costs on sale of intellectual property, incentive payments 913              
Transaction costs on sale of intellectual property, assignment and success fees 260              
Transaction costs on sale of intellectual property, other costs € 64              
Foundation Fighting Blindness                
Other Income [Line Items]                
Grant income       € 0        
Clinical support agreement | Foundation Fighting Blindness                
Other Income [Line Items]                
Funding receivable under agreement | $               $ 7,500,000
Agreement with RSRT that focuses on the design and development of editing oligonucleotides, phase one                
Other Income [Line Items]                
Grant income   € 441 € 574          
Agreement with RSRT that focuses on the design and development of editing oligonucleotides, phase one | Maximum                
Other Income [Line Items]                
Funding receivable under agreement             € 1,015  
Agreement with RSRT that focuses on the design and development of editing oligonucleotides, phase two                
Other Income [Line Items]                
Funding received under agreement         € 0      
Agreement with RSRT that focuses on the design and development of editing oligonucleotides, phase two | Maximum                
Other Income [Line Items]                
Funding receivable under agreement | $           $ 8,150,000